CHCharlotte M. Höög

Charlotte M. Höög

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Charlotte M. Höög has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Lars-Åke Bark

    Department for Clinical Science and Education, Karolinska Institutet, Södersjukhuset, Section for Gastroenterology and Hepatology, Stockholm, Sweden

    2 shared publications
  • Olle Broström

    Department for Clinical Science and Education, Karolinska Institutet, Södersjukhuset, Section for Gastroenterology and Hepatology, Stockholm, Sweden

    2 shared publications
  • Urban Sjöqvist

    Department for Clinical Science and Education, Karolinska Institutet, Södersjukhuset, Section for Gastroenterology and Hepatology, Stockholm, Sweden

    2 shared publications
  • Elisabeth Almer Boström

    Division of Oral Diseases, Department of Dental Medicine, Karolinska Institutet, Huddinge, Sweden

    1 shared publication
  • Jacob Gorsetman

    Department of Medicine, Danderyd Hospital

    1 shared publication
  • Juan Arkani

    Department of Gastroenterology, Ersta Hospital

    1 shared publication

Latest Publications

  • Open Access

    Systemic Chemokine Levels with “Gut-Specific” Vedolizumab in Patients with Inflammatory Bowel Disease—A Pilot Study

    by Stephanie Zwicker, Ronaldo Lira-Junior, Charlotte Höög, Sven Almer, Elisabeth A. Boström

    Vedolizumab, a gut-specific biological treatment for inflammatory bowel disease (IBD), is an antibody that binds to the α4β7 integrin and blocks T-cell migration into intestinal mucosa. We aimed to investigate chemokine levels in serum of IBD-patients treated with vedolizumab. In this pilot study, we included 11 IBD patients (8 Crohn’s disease, 3 ulcerative colitis) previously non-respondent to anti-tumor necrosis factor (TNF)-agents. Patients received vedolizumab at week 0, 2 and 6 and were evaluated for clinical efficacy at week 10. Clinical characteristics and routine laboratory parameters were obtained and patients were classified as responders or non-responders. Expression of 21 chemokines in serum was measured using Proximity Extension Assay and related to clinical outcome. At week 10, 6 out of 11 patients had clinically responded. Overall expression of CCL13 increased after treatment. In non-responders, expression of CCL13 and CXCL8 increased after treatment, and CCL20 and CXCL1 expressions were higher compared to responders. In responders, CCL28 decreased after treatment. C-reactive protein (CRP) correlated negatively with 6 chemokines before therapy, but not after therapy. Systemic CCL13 expression increases in IBD-patients after vedolizumab therapy and several chemokine levels differ between responders and non-responders. An increased CCL13-level when starting vedolizumab treatment, might indicate potential prognostic value of measuring chemokine levels when starting therapy with vedolizumab. This study provides new information on modulation of systemic chemokine levels after vedolizumab treatment.


  • Capsule endoscopic findings correlate with fecal calprotectin and C-reactive protein in patients with suspected small-bowel Crohn’s disease

    by Charlotte M. Höög, Lars-Åke Bark, Olle Broström, Urban Sjöqvist

    Objective. Capsule endoscopy (CE) is a sensitive method for detecting inflammatory lesions in the small bowel. Such lesions may be due to Crohn’s disease but also to other causes and a histological diagnosis may be difficult to achieve in the small bowel. The aim of the study was to find a possible correlation between capsule endoscopic findings, biochemical parameters, and symptoms in patients with suspected or known small-bowel Crohn´s disease. Materials and methods. Thirty patients with inflammatory lesions in the small bowel diagnosed by CE were included. CE findings of inflammation were graded using the Lewis score. C-reactive protein (CRP) and fecal calprotectin were used as biochemical parameters. Symptoms were graded using the Harvey–Bradshaw index. The patients were followed up after 9 months with a second CE, CRP, fecal calprotectin, and Harvey–Bradshaw index. Results. There was a significant persistent correlation between endoscopic inflammation and fecal calprotectin (p = 0.003 at inclusion and p < 0.001 at follow-up). CRP was correlated to endoscopic inflammation at inclusion (p = 0.006), but not at follow-up. Symptoms were not correlated with endoscopic inflammation. Conclusion. Inflammatory lesions in the small bowel diagnosed by CE in patients with suspected Crohn´s disease are correlated to fecal calprotectin and CRP, but not to symptoms.


  • Open Access

    Capsule Retentions and Incomplete Capsule Endoscopy Examinations: An Analysis of 2300 Examinations

    by Charlotte M. Höög, Lars-Åke Bark, Juan Arkani, Jacob Gorsetman, Olle Broström, Urban Sjöqvist

    Aim. To evaluate capsule endoscopy in terms of incomplete examinations and capsule retentions and to find risk factors for these events.Material and Methods. This retrospective and consecutive study includes data from 2300 capsule enteroscopy examinations, performed at four different hospitals in Stockholm, Sweden from 2003 to 2009.Results. The frequency of incomplete examinations was 20%. Older age, male gender, suspected, and known Crohn's disease were risk factors for an incomplete examination. The PillCam capsule had the highest rate of completed examinations. Capsule retention occurred in 1.3% (). Risk factors for capsule retention were known Crohn's disease and suspected tumor. Complications of capsule retention were acute obstructive symptoms in six patients and one death related to complications after acute surgical capsule retrieval.Conclusion: Capsule endoscopy is considered a safe procedure, although obstructive symptoms and serious complications due to capsule retention can be found in a large series of patients.